Materiały źródłowe

• #1 Pulmonary hypertension – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20350702

  There’s no cure for pulmonary hypertension. But treatments can improve symptoms and help you live longer. Treatment also can help keep the disease from getting worse. […] It often takes some time to find the best pulmonary hypertension treatment. The treatments are often complex. You usually need a lot of health checkups. […] If you have pulmonary hypertension, you may get medicines to treat your symptoms and help you feel better. Medicines also may be used to treat or prevent complications. Treatment may include: […] Medicines to relax blood vessels, called vasodilators. These medicines open narrowed blood vessels and improve blood flow. The medicine may be breathed in, taken by mouth or given through a vein. Sometimes, it’s given continuously through a small pump attached to the body.

• #1

  https://www.nhs.uk/conditions/pulmonary-hypertension/treatment/

  Pulmonary hypertension cannot be cured, but treatments can reduce your symptoms and help you manage your condition. […] If pulmonary hypertension is caused by blood clots that block the pulmonary arteries, you may be offered anticoagulant medicines to prevent more clots forming. […] There are many treatments for pulmonary hypertension. Which treatment or combination of treatments you’ll be offered will depend on a number of factors, including what type of pulmonary hypertension you have, what’s causing it and the severity of your symptoms. […] Treatments include: anticoagulant medicines such as warfarin to help prevent blood clots, diuretics (water tablets) to remove excess fluid from the body caused by heart failure, home oxygen therapy this involves inhaling air that contains a higher concentration of oxygen than normal, digoxin this can improve your symptoms by strengthening your heart muscle contractions and slowing down your heart rate.

• #1 Treating and Managing Pulmonary Arterial Hypertension | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/treating-and-managing

  Although there is no cure for pulmonary arterial hypertension, there are medications and treatment options that can slow the progression of the disease and improve your quality of life. […] Treatment options vary from person to person, so you will want to work closely with your healthcare provider to determine the best plan for you. […] Because PAH is such a rare disease, it is extremely valuable to see a specialist at an accredited center to ensure you are getting the most up-to-date treatment options. […] PAH-specific medications come in multiple forms: oral, inhaled and subcutaneous (meaning delivered by an injection or IV). The medicines for PAH work in a few ways. Some allow blood to flow more easily through the arteries of your lungs. Others help your heart and lungs work better.

• #1 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  Tyvaso, like Ventavis, is also an inhaled prostanoid medication. It was approved in July 2009 for use in patients with WHO group I PAH that are suffering from moderate to severe symptoms in order to increase walk distance. The dosing regimen is not as frequent as Ventavis, only requiring use 4 time per day with increasing number of breaths per dose as the patient is optimized on therapy. The medication is delivered via a specialized and individualized nebulizer device. The side effect profile is once again similar to that of the previously discussed medication but again tends to have less flushing and diarrhea. Tyvaso does tend to cause increased sore throat and cough with initial use. […] This is the first oral medication specifically approved for the treatment of pulmonary hypertension. It is approved for patients with advanced disease due to PAH or connective tissue disease associated pulmonary hypertension. In research studies, the medication was shown to increase exercise tolerance and decrease clinical worsening compared to placebo. Approximately 10% of patients taking this drug will develop elevated liver function tests. As a result, monthly monitoring is required. A smaller percentage of patients may also experience a decrease in hemoglobin. Periodic monitoring of blood counts and liver function test is required. This drug is absolutely contraindicated in women who are or could become pregnant. For sexually active women, two methods of birth control are recommended and monthly pregnancy tests are also mandatory.

• #1 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  As a result of small but favorable studies, sildenafil was tested and found useful in trials for patients with New York Heart Association (NYHA) Class II-IV pulmonary arterial hypertension. Sildenafil is an active vasodilator and allows for improved pulmonary blood flow. Sildenafil is currently approved for patient with PAH in the formulation of Revatio. The usual dose of 20 mg three times daily is the current recommendation by the FDA. However, patients with severe PAH may often require higher, and more frequent, dosing. Although used for erectile dysfunction in men, sildenafil has not been shown to affect sexual desire in men, nor does it have any effect in women. Side effects of sildenafil include headache, back pain, and flushing. The use of sildenafil is contraindicated in patients using nitrate containing medications such as isordil or sub-lingual nitroglycerin. Other drug interactions include alpha-blockers (such as Doxazosin), certain antibiotics, and verapamil (which may increase sildenafil serum concentration). Bosentan and sildenafil, when taken together, co-interact and result in elevated bosentan and decreased sildenafil levels. Patients with coronary artery disease need to notify their physician before using sildenafil.

• #1 Treatments – Pulmonary Hypertension Association

  https://phassociation.org/patients/treatments/

  Although there is no cure for pulmonary hypertension, many treatment options are available and more are on the horizon. Treatments include what health care providers call conventional medical therapies as well as oral, inhaled, subcutaneous (into the skin), and intravenous (into the vein) options. Depending on the severity of PH, heart or lung transplant may also be an option. […] Remember that each patient is different. It is essential that you talk to your own doctor about what treatment options are best for you. […] Conventional medical therapies include calcium channel blockers, digoxin, diuretics, oxygen, and warfarin. […] Oral treatments include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. […] Inhaled treatment options, including prostacyclins, relieve shortness of breath.

• #1 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  Like Flolan and Remodulin, Ventavis is also a prostanoid medication. As of April 2005, Ventavis was approved for use in patients in World Health Organization (WHO) group I which includes patients with idiopathic PAH, familial PAH, associated PAH (collagen vascular disease, congenital heart disease, stimulant associated, portal hypertension, etc), PAH associated with venous or capillary disease, and persistent PH of the newborn. Unlike Flolan, Veletri and Remodulin, Ventavis is an inhaled medication, administered via a nebulizer. It is recommended for use between 6-9 times daily. Side effect profile of Ventavis is similar to Flolan, Veletri and Remodulin. However, patients report less flushing diarrhea. Patients with a history of asthma or emphysema may need to be cautious at the time of initiation since worsening cough and breathing may result.

• #1 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  This is the first drug specifically approved for the treatment of pulmonary hypertension. Flolan is the most effective drug for the treatment of advanced disease. Studies have shown the drug to be effective in pulmonary arterial hypertension (PAH), as well as pulmonary hypertension related to scleroderma, lupus, congenital heart disease, diet-pill associated and stimulant associated pulmonary hypertension (PH). Flolan requires a substantial commitment from the patient. This medication is delivered by a continuous infusion via a special intravenous catheter. The medication must be mixed on a daily basis and kept refrigerated. Meticulous attention must be paid to catheter care to prevent serious infections. Common side effects include headache, jaw discomfort, flushing, rashes, and stomach upset. In patients with advanced disease, this medication improves exercise capacity and survival. Periodic monitoring of blood counts is required.

• #1 Pulmonary Hypertension: Symptoms, Treatment

  https://my.clevelandclinic.org/health/diseases/6530-pulmonary-hypertension-ph

  Pulmonary hypertension treatment depends on the type of PH you have and your other medical conditions. Your healthcare team will tailor treatment to your individual needs. […] Right now, only two types of PH can be treated directly: Pulmonary artery hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH). […] Treatment for pulmonary arterial hypertension (PAH) includes: Calcium channel blockers. These medications can help lower the blood pressure in your pulmonary arteries and throughout your body. Diuretics. These water pills help your body clear out extra fluid. Oxygen therapy. You may need this treatment if you don’t have enough oxygen in your blood. Pulmonary vasodilators. These medications help your pulmonary arteries relax and open up better. This improves blood flow and lowers the strain on your heart.

• #1 Advances in the Treatment of Pulmonary Arterial Hypertension | ECR Journal

  https://www.ecrjournal.com/articles/advances-treatment-pulmonary-arterial-hypertension?language_content_entity=en

  Phosphodiesterase-5 inhibitors (PDE5i) block the degradation of the second messenger of nitric oxide, cyclic guanosine monophosphate (cGMP). Due to high PDE5 expression levels in pulmonary vessels compared with other organs, the oral PDE5i sildenafil induces selective pulmonary vasodilatation without undesirable systemic side effects. Sildenafil is very well tolerated and was the first PDE5i to be approved for use in PAH. Considerable differences between the currently available PDE5i sildenafil, vardenafil and tadalafil were noted in an acute vasodilator trial with regard to the required doses, and selectivity for the pulmonary versus systemic circulation. Tadalafil is the second PDE5i to be investigated in a randomised controlled trial in patients with PAH. […] […] Several uncontrolled clinical trials have demonstrated that combinations of two or more of the specific PAH medications may improve and/or stabilise previously unstable patients. Despite the lack of randomised controlled trials, combination therapies have been suggested by various guidelines for patients failing on initial monotherapies. Due to the high costs of each individual drug, sequential addition of drugs to an ongoing first-line treatment is currently the preferred approach. […]

• #1 Pulmonary Arterial Hypertension Treatment

  https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/06/10/17/56/pulmonary-arterial-hypertension-treatment

  Drugs targeting the three traditional treatment pathways (nitric oxide, endothelin, and prostacyclin) significantly increased 6-minute walk distance (6MWD) and reduced the likelihood of clinical worsening compared to placebo in patients with PAH. […] Combination therapy targeting both the nitric oxide and endothelin pathway was associated with the greatest benefit in terms of 6MWD, time to clinical worsening, mortality, and NT-proBNP, compared with single therapy targeting the nitric oxide, endothelin, or prostacyclin pathways. […] Drugs targeting the three traditional treatment pathways significantly improve outcomes in PAH. Combination therapy targeting the endothelin and nitric oxide pathways was associated with the greatest benefit in terms of 6MWD and time to clinical worsening compared with single therapy targeting the nitric oxide, endothelin, or prostacyclin pathways. PAH therapy may be less effective in patients with some comorbidities, including older age, obesity, systemic hypertension, diabetes, and coronary artery disease.

• #1 Pulmonary hypertension – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/pulmonary-hypertension/diagnosis-treatment/drc-20350702

  If medicines do not help control the symptoms of pulmonary hypertension, surgery may be recommended. Surgeries and procedures to treat pulmonary hypertension may include: […] Atrial septostomy. This treatment may be done if medicines don’t control pulmonary hypertension symptoms. In an atrial septostomy, a doctor creates an opening between the upper left and right chambers of the heart. The opening reduces the pressure on the right side of the heart. […] Lung or heart-lung transplant. Sometimes, a lung or heart-lung transplant may be needed, especially for younger people who have idiopathic pulmonary arterial hypertension. After a transplant, medicine must be taken for life to prevent the body from rejecting the new organ.

• #1

  https://www.nhs.uk/conditions/pulmonary-hypertension/treatment/

  There are also a number of specialist treatments for pulmonary hypertension that help relax the arteries in the lungs and reduce the blood pressure in the lungs. […] Other treatments that are sometimes used are: endothelin receptor antagonists such as bosentan, ambrisentan and macitentan, phosphodiesterase 5 inhibitors sildenafil and tadalafil, prostaglandins epoprostenol, iloprost and treprostinil, soluble guanylate cyclase stimulators such as riociguat, calcium channel blockers nifedipine, diltiazem, nicardipine and amlodipine. […] Some people with pulmonary hypertension may need surgery. The types of surgery currently used are: pulmonary endarterectomy an operation to remove old blood clots from the pulmonary arteries in the lungs in people with chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty a new procedure where a tiny balloon is guided into the arteries and inflated for a few seconds to push the blockage aside and restore blood flow to the lung; it may be considered if pulmonary endarterectomy is not suitable, and has been shown to lower blood pressure in the lung arteries, improve breathing, and increase the ability to exercise, atrial septostomy a small hole is made in the wall between the left and right atria of the heart using a cardiac catheter, a thin, flexible tube inserted into the heart’s chambers or blood vessels; it reduces the pressure in the right side of the heart, so the heart can pump more efficiently and the blood flow to the lungs can be improved, transplant in severe cases, a lung transplant or a heart-lung transplant may be needed; this type of surgery is rarely used because effective medicine is available.

• #1 Mechanisms and treatment of pulmonary arterial hypertension | Nature Reviews Cardiology

  https://www.nature.com/articles/s41569-024-01064-4

  Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. […] Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach.

• #1 New PAH Treatments Increase Patient Options – Pulmonary Hypertension Association

  https://phassociation.org/new-pah-treatments-increase-patient-options/

  Pulmonary hypertension treatment has come a long way since PHA’s founding in 1991. In the past week, the Food and Drug Administration approved the 15th and 16th treatments for pulmonary arterial hypertension. […] Last Friday, the FDA approved Johnson & Johnson’s Opsynvi, the first and only once-daily combination pill of macitentan and tadalafil. […] On Tuesday, the FDA approved Merck’s Winrevair (sotatercept-csrk), the first PAH drug that works on a new biological pathway different from those targeted by 14 existing FDA-approved treatments. […] Both treatments represent breakthroughs for the PH community. A once-daily pill offers increased convenience that can improve quality of life. And medication that works on a new pathway offers hope that PH can be reversed. […] Opsynvi can be taken by people who currently take 10 mg a day of macitentan and 40 mg of tadalafil in separate tablets.

• #1 Treating and Managing Pulmonary Arterial Hypertension | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/treating-and-managing

  It is also important to stay up to date on all recommended vaccinations. […] Quitting smoking and avoiding secondhand smoke is one of the most important decisions you can make. […] Though PAH may make you feel fatigued, it is important to stay active and exercise as much as possible. […] Eating healthy will be an important part of managing your disease. […] Pregnancy can put strain on your body and for a patient with PAH be possibly life-threatening, so this is a subject you should discuss with your healthcare provider prior to becoming pregnant. […] If Left Untreated, PAH Can Result in the Following: Right heart failure can occur due to increased stress on your heart. […] The most common cause of death in PAH is right heart ventricular failure. […] The outcome for untreated PAH is poor.

• #1 Treatment and prognosis of pulmonary arterial hypertension in adults (group 1) – UpToDate

  https://www.uptodate.com/contents/treatment-and-prognosis-of-pulmonary-arterial-hypertension-in-adults-group-1

  Treatment and prognosis of pulmonary arterial hypertension in adults (group 1) […] The treatment of PAH with PH-specific therapy; etiology and pathogenesis of PAH; and clinical manifestations, diagnosis and classification of PH are discussed separately. […] Treatment for the most part follows recommendations issued by several guideline societies. […] Patients with group 1 PAH should exercise as tolerated, receive routine vaccinations, be counseled against smoking (and vaping), and maintain a normal body mass index. When indicated, they should also be treated with supportive measures including oxygen, diuretics, and anticoagulants. Patients should be additionally treated for any comorbidities known to be associated with or worsen PH. […] Exercise and pulmonary rehabilitation — Patients with PAH should exercise regularly. Indications for referral to a pulmonary exercise rehabilitation program are extrapolated from the chronic obstructive pulmonary disease population, but the benefits appear to be similar. […] In a 2019 statement issued by the European Respiratory Society that reviewed 20 trials, exercise training was consistently associated with improved exercise capacity, muscular function, quality of life, and, possibly, right ventricular function and pulmonary hemodynamics.

• #1 Natural Ways to Reduce Pulmonary Hypertension: Tips and Strategies

  https://www.healthline.com/health/how-to-reverse-pulmonary-hypertension-naturally

  Adopting healthy lifestyle behaviors may help lower blood pressure in your lungs and ease your symptoms. For example, you can try adjusting your diet, exercising more, and avoiding stimulants. […] While there isn’t a cure for the condition, medications, treatments, and lifestyle changes can help. […] Regular aerobic exercise can help you keep your heart healthy. This is especially important because keeping your heart and lungs functioning at their best can be difficult with pulmonary hypertension. […] A 2021 study suggests that a supervised exercise-based rehabilitation program is generally safe for most people with pulmonary hypertension who are otherwise medically stable. It found that the program could increase their capacity to do more exercise. […] By reducing the sodium in your diet, you can help prevent your pulmonary hypertension from getting worse.

• #1 Pulmonary Hypertension | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/pulmonary-hypertension

  Anticoagulants. Often called blood thinners, these drugs keep blood from clotting, allowing circulating blood to flow more easily. […] Diuretics. These medications minimize water retention which can make the heart work harder by making the kidneys produce more urine. […] Digoxin. This drug can help the right side of the heart pump better, but patients receiving it need to be closely monitored. […] Supplemental oxygen. For patients with low blood oxygen levels, concentrated oxygen may be delivered using in-home machines and portable devices. […] When all other options have failed, patients with severe pulmonary hypertension and poor quality of life may be candidates for lung transplantation or heart-lung transplantation. […] Adequate rest, a healthy diet, exercise and stress reduction can help control pulmonary hypertension. People with the disease should avoid smoking, becoming pregnant, using birth control pills and being at high altitudes. […] Pulmonary hypertension treatment is often highly complex and patients require intensive ongoing follow-up. This comprehensive care is available from the specialists of the UCSF Pulmonary Hypertension Program.

• #1 Natural Ways to Reduce Pulmonary Hypertension: Tips and Strategies

  https://www.healthline.com/health/how-to-reverse-pulmonary-hypertension-naturally

  Poor sleep is associated with health problems like high blood pressure and obesity. You can improve your health by prioritizing sleep quality and quantity. […] Certain external conditions can exacerbate pulmonary hypertension symptoms because they put strain on the heart and lungs. Therefore, you may need to avoid taking very hot baths or showers and steer clear of saunas and hot tubs. […] While natural treatments and healthy lifestyle changes may help improve your symptoms, they should not be viewed as replacements for evidence-based treatments. […] If you have been diagnosed with pulmonary hypertension, be sure to discuss all treatment options and lifestyle adjustments you can make to reverse or at least better manage your symptoms.

• #1 Treating and Managing Pulmonary Arterial Hypertension | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/treating-and-managing

  Treatment aims to restore balance among one or more of three substances that are produced by your lungs: nitric oxide, endothelin, and prostacyclin. […] Your healthcare provider may recommend supportive treatment to manage your PAH. […] One or more of the following medications may be recommended: Blood thinners to prevent blood clots, Digoxin to help your heart beat regularly, Water pills, also called diuretics, to remove extra fluid from your body, Oxygen therapy to make sure you are getting enough oxygen. […] Surgery may be recommended in some situations. […] Atrial septostomy is a procedure that creates an opening between the upper left and right chambers of the heart. The opening reduces the pressure on the right side of the heart. […] Many pulmonary hypertension care centers require visits every few months and regular testing such as echocardiograms and 6-minute walk testing.

• #1 Idiopathic Pulmonary Arterial Hypertension Treatment & Management: Approach Considerations, Calcium Channel Blocker Therapy, PAH-Specific Therapy

  https://emedicine.medscape.com/article/301450-treatment

  A newer concept of goal-oriented therapy has been developed after observations that patients with an inadequate clinical response to an initial therapy have a much worse prognosis. […] Finally, for patients who do not fall into the above categories, reference to the ACCP Guideline for specific evidence-based scenarios and simultaneous referral to an expert PAH center is suggested. […] It is important to perform vasoactivity testing in patients with IPAH before prescribing PAH-specific therapy. […] Patients who do not have an acute vasodilator response to a vasodilator challenge have a worse prognosis on long-term oral PAH-specific therapy compared with those who have an initial response. […] Continuous intravenous prostanoid therapy is delivered via an ambulatory infusion pump. […] Patients with IPAH may benefit from therapy with anticoagulants, digoxin, diuretics, or supplemental oxygen.

• #2

  https://www.nhs.uk/conditions/pulmonary-hypertension/treatment/

  Pulmonary hypertension cannot be cured, but treatments can reduce your symptoms and help you manage your condition. […] If pulmonary hypertension is caused by blood clots that block the pulmonary arteries, you may be offered anticoagulant medicines to prevent more clots forming. […] There are many treatments for pulmonary hypertension. Which treatment or combination of treatments you’ll be offered will depend on a number of factors, including what type of pulmonary hypertension you have, what’s causing it and the severity of your symptoms. […] Treatments include: anticoagulant medicines such as warfarin to help prevent blood clots, diuretics (water tablets) to remove excess fluid from the body caused by heart failure, home oxygen therapy this involves inhaling air that contains a higher concentration of oxygen than normal, digoxin this can improve your symptoms by strengthening your heart muscle contractions and slowing down your heart rate.

• #2 Treatments – Pulmonary Hypertension Association

  https://phassociation.org/patients/treatments/

  Although there is no cure for pulmonary hypertension, many treatment options are available and more are on the horizon. Treatments include what health care providers call conventional medical therapies as well as oral, inhaled, subcutaneous (into the skin), and intravenous (into the vein) options. Depending on the severity of PH, heart or lung transplant may also be an option. […] Remember that each patient is different. It is essential that you talk to your own doctor about what treatment options are best for you. […] Conventional medical therapies include calcium channel blockers, digoxin, diuretics, oxygen, and warfarin. […] Oral treatments include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. […] Inhaled treatment options, including prostacyclins, relieve shortness of breath.

• #2 Treatments for Pulmonary Arterial Hypertension: Pills, Inhaled Drugs, Oxygen

  https://www.webmd.com/lung/pah-treatment-options

  While theres no cure for pulmonary arterial hypertension (PAH), many types of medicines and procedures can ease your symptoms and make your day-to-day life better. […] The first step of any plan is to treat the cause of your PAH. […] To help you choose a treatment plan, your doctor will see how severe your symptoms are and how much your disease keeps you from being active. […] These work in a few ways. Some let blood flow more easily through the arteries in your lungs, and others help your heart and lungs work better. […] Calcium channel blockers are drugs that lower your blood pressure by relaxing the muscles that control the arteries. […] Digoxin is a daily pill that helps the heart beat more strongly, which can help if the cause of your PAH is heart failure or an irregular heart rhythm.

• #2 Pulmonary Arterial Hypertension (PAH): Symptoms and Treatment

  https://my.clevelandclinic.org/health/diseases/23913-pulmonary-arterial-hypertension

  Calcium channel blockers. These medications help lower the blood pressure in your pulmonary arteries and throughout your body. […] Diuretics. These water pills get rid of extra fluid in your body and reduce swelling. […] Oxygen therapy. You may need this treatment if you dont have enough oxygen in your blood. Supplemental oxygen can help people during rest, sleep or exercise. […] Pulmonary vasodilators. These medications help your pulmonary arteries relax and open up better. This relieves the strain on your heart and helps ease your symptoms. […] A last resort option for some people with severe PAH is a lung transplant. This surgery may give you one or two new lungs. A heart-lung transplant gives you a new heart as well. […] Medications that treat PAH come in several different forms: Oral. To help the blood vessels in your lungs relax, and to prevent them from becoming narrow. These medications may help you be more physically active.

• #2

  https://www.nhs.uk/conditions/pulmonary-hypertension/treatment/

  There are also a number of specialist treatments for pulmonary hypertension that help relax the arteries in the lungs and reduce the blood pressure in the lungs. […] Other treatments that are sometimes used are: endothelin receptor antagonists such as bosentan, ambrisentan and macitentan, phosphodiesterase 5 inhibitors sildenafil and tadalafil, prostaglandins epoprostenol, iloprost and treprostinil, soluble guanylate cyclase stimulators such as riociguat, calcium channel blockers nifedipine, diltiazem, nicardipine and amlodipine. […] Some people with pulmonary hypertension may need surgery. The types of surgery currently used are: pulmonary endarterectomy an operation to remove old blood clots from the pulmonary arteries in the lungs in people with chronic thromboembolic pulmonary hypertension, balloon pulmonary angioplasty a new procedure where a tiny balloon is guided into the arteries and inflated for a few seconds to push the blockage aside and restore blood flow to the lung; it may be considered if pulmonary endarterectomy is not suitable, and has been shown to lower blood pressure in the lung arteries, improve breathing, and increase the ability to exercise, atrial septostomy a small hole is made in the wall between the left and right atria of the heart using a cardiac catheter, a thin, flexible tube inserted into the heart’s chambers or blood vessels; it reduces the pressure in the right side of the heart, so the heart can pump more efficiently and the blood flow to the lungs can be improved, transplant in severe cases, a lung transplant or a heart-lung transplant may be needed; this type of surgery is rarely used because effective medicine is available.

• #2 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  Letairis is in the same class of medication as Tracleer. It gained its initial FDA approval in May 2009 for treatment of PAH WHO group I to improve exercise ability and delay clinical worsening. The studies that established effectiveness predominantly included patients with moderate to severe disease with idiopathic, heritable or PAH associated with connective tissue diseases. Letairis is a once a day medications (Tracleer needs to be taken twice a day). Unlike Tracleer, it has not been shown to have the predilection to increase liver enzymes and was approved by the FDA in early 2011 to not require routine blood tests to evaluate the liver. Treatment with Letairis does require all women of childbearing potential to use two acceptable methods of contraception and have monthly pregnancy tests.

• #2 Pulmonary Arterial Hypertension: Drugs and Medications

  https://www.healthline.com/health/pulmonary-hypertension/pulmonary-arterial-medications

  Warfarin (Coumadin) is one example of an anticoagulant. […] Endothelin receptor antagonists work by reversing the effect of endothelin. […] All of the drugs in this group are oral drugs. […] Common side effects of endothelin receptor antagonists can include: headache; swelling; anemia (low red blood cell levels); bronchitis. […] Serious side effects of these drugs can include: Low blood hemoglobin levels. […] Riociguat (Adempas), an oral tablet, is one example of this type of drug. […] Your doctor may prescribe other drugs to treat your PAH. […] These drugs work like vasodilators. They open narrowed blood vessels, which helps blood flow through your lungs more easily. […] High doses of calcium channel blockers can help a small number of people with PAH. […] Digoxin helps your heart pump more effectively, which causes more blood to flow. It also causes more blood to reach your lungs.

• #2 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  This is the first drug specifically approved for the treatment of pulmonary hypertension. Flolan is the most effective drug for the treatment of advanced disease. Studies have shown the drug to be effective in pulmonary arterial hypertension (PAH), as well as pulmonary hypertension related to scleroderma, lupus, congenital heart disease, diet-pill associated and stimulant associated pulmonary hypertension (PH). Flolan requires a substantial commitment from the patient. This medication is delivered by a continuous infusion via a special intravenous catheter. The medication must be mixed on a daily basis and kept refrigerated. Meticulous attention must be paid to catheter care to prevent serious infections. Common side effects include headache, jaw discomfort, flushing, rashes, and stomach upset. In patients with advanced disease, this medication improves exercise capacity and survival. Periodic monitoring of blood counts is required.

• #2 Medications for PAH – Lung Foundation Australia

  https://lungfoundation.com.au/blog/medications-for-pah/

  Prostacyclins help the blood vessels relax by mimicking prostaglandin, a substance in the blood that is often low in PAH patients. […] People with PAH have too much endothelin in their blood. ERAs block endothelin, a substance that helps the blood vessels constrict. […] PDE-5 inhibitors allow the lungs to make more of their own natural vasodilators, which relax the blood vessels and allow more blood to flow. […] sGC stimulators help in chemical reactions that improve blood flow in the lungs. […] Other medications can be used as supportive medications, and may include fluid tablets, blood thinners and medications to help relieve symptoms. […] If the patient has fluid retention, diuretics remove excessive fluid. […] A lot of people living with PAH have an iron deficiency which can reduce exercise capacity. […] Only a small amount of people with PAH will need calcium channel blockers. These drugs help encourage more blood flow by relaxing blood vessel walls.

• #2 Pulmonary Arterial Hypertension Treatment & Management: Approach Considerations, Oxygen Supplementation, Pharmacologic Therapy

  https://emedicine.medscape.com/article/303098-treatment

  Supportive therapy includes oxygen therapy, diuretics, digoxin, exercise, and anticoagulation. Decisions regarding starting each of these therapies should be made on a patient-by-patient basis in the appropriate clinical scenario. These therapies are not specific to PAH and are frequently used in all WHO groups of pulmonary hypertension. […] In contrast, advanced vasodilatory therapies are largely confined to cases of PAH. Guidelines recommend against using these advanced therapies in cases of pulmonary hypertension from left-sided heart disease or pulmonary disease, and initiation of these should be in specialized centers and by providers well experienced in treating PAH. […] Oxygen has proved beneficial for reducing patient mortality in selected patients with pulmonary hypertension. Two large trials demonstrated a definite mortality benefit for patients with WHO group 3 pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD).

• #2 Pulmonary Hypertension: Symptoms, Treatment

  https://my.clevelandclinic.org/health/diseases/6530-pulmonary-hypertension-ph

  Treatment for CTEPH includes: Anticoagulants. These medicines help prevent blood clots. Balloon atrial septostomy (BAS). This procedure is typically used for babies with critical heart defects. However, it’s also used for adults with pulmonary hypertension. It’s a bridge that helps keep you stable as you wait for a lung transplant. Balloon pulmonary angioplasty (BPA). This catheter-based procedure uses a balloon to widen your pulmonary artery. It’s usually done if you can’t have open surgery. Medication. A soluble guanylate cyclase stimulator (SGCS) may help slow down the disease progression. Pulmonary endarterectomy (PEA). This surgery removes blood clots from your lungs. It’s currently the only possible cure for pulmonary hypertension, and it’s only for people with CTEPH. […] Treatment for PH caused by heart or lung problems focuses on managing the underlying conditions. Because so many different heart and lung conditions cause PH, treatment plans can be vastly different from person to person.

• #2 Pulmonary Arterial Hypertension Treatment & Management: Approach Considerations, Oxygen Supplementation, Pharmacologic Therapy

  https://emedicine.medscape.com/article/303098-treatment

  Diuretics are indicated in patients with PAH who have signs of right-sided heart volume overload, as evidenced by lower extremity edema, ascites, hepatic congestion, or elevated jugular venous pressure. […] Anticoagulation (specifically, with warfarin) may be helpful because evidence suggests that patients with idiopathic PAH (IPAH) develop thrombotic arteriopathy (with abnormalities of blood coagulation factors, antithrombotic factors, and the fibrinolytic system). […] Advanced therapies should be considered after right-sided heart catheterization for PAH patients in functional class II, III, or IV. […] For patients with WHO functional class II or III disease, experts often begin with a combination of two oral agents targeting separate pathways. […] Balloon atrial septostomy involves creation of an atrial right-to-left shunt by graded balloon dilation of the atrial septum.

• #2 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  This very old medication is used in certain patients with pulmonary hypertension, particularly patients with advanced disease. It may help the heart pump more effectively. Patients with kidney failure may need to have Digoxin levels monitored very carefully. […] Patients with low oxygen levels benefit from oxygen therapy. Low oxygen levels in the lungs causes the pulmonary arteries to constrict, thereby worsening pulmonary hypertension. Some patients may require supplemental oxygen only with exertion or sleep; others will need continuous therapy.

• #2 Pulmonary Hypertension Medical Management and Treatment | UPMC

  https://www.upmc.com/services/pulmonology/our-services/pulmonary-hypertension/treatments/medical-management

  The treatment and management of pulmonary hypertension (PH) depends on the specific kind a person has. […] In the last 25 years, the medical community has made remarkable progress in treating these forms of PH. They often respond to one form of therapy or a combination of therapies. […] Our experts at the UPMC Comprehensive Pulmonary Hypertension Program work with each person to prescribe the right treatment or management method. This helps improve daily function and prolong life. […] There are currently 12 FDA-approved drugs for PAH. […] Other medical therapies for PAH may include: Oxygen inhaled by patients via a nasal cannula or face mask. Diuretics medicine that rids the body of excess fluid that puts pressure on the heart. Calcium channel blockers (CCB) medicine that helps to decrease blood pressure. Warfarin (Coumadin) medicine that thins blood and prevents it from clotting. […] Current research has focused on combining existing and newer therapies to improve outcomes. […] In our program, we are always at the cutting edge of new medical therapies for PH, either directly through clinical trials or through close communication with PH drug developers.

• #2 Pulmonary Arterial Hypertension Treatment

  https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/06/10/17/56/pulmonary-arterial-hypertension-treatment

  The fact that combination therapy targeting the nitric oxide and endothelin pathways was associated with the greatest clinical benefit than any other single pathway therapy is relevant for clinical practice and further supports the Class I recommendation made by the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension on initial combination treatment for low- and intermediate-risk PAH patients.

• #2 Pulmonary Hypertension: Diagnosis and Treatment | AAFP

  https://www.aafp.org/pubs/afp/issues/2016/0915/p463.html

  Patients with a mean pulmonary arterial pressure decrease of more than 10 mm Hg to less than 40 mm Hg and with an unchanged or increased cardiac output when challenged are considered vasoreactive. […] Other treatments may include an endothelin receptor antagonist (bosentan [Tracleer]), a phosphodiesterase type 5 inhibitor (sildenafil [Revatio]), or a soluble guanylate cyclase stimulator (riociguat [Adempas]). […] A pulmonary endarterectomy performed at a center of excellence can be curative and is first-line therapy in patients with chronic thromboembolic pulmonary hypertension who are surgical candidates. […] Patients who are not surgical candidates can be considered for targeted medical therapies also used to treat pulmonary arterial hypertension. […] The use of therapies targeted at pulmonary arterial hypertension is strongly discouraged.

• #2 Pulmonary Hypertension: Diagnosis, Management, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6433622/

  Balloon pulmonary angioplasty (BPA) is another treatment option for patients who are technically inoperable or for those in whom the risk-benefit ratio for PEA is unacceptable. […] Since 1999, PAH has become a treatable cardiovascular disease with improved survival and decreased morbidity. The exact classification of PH is important because prognosis and treatment responses differ among different groups of patients. Combination therapy in patients with newly diagnosed PAH should be considered for treatment, and re-evaluation during follow-up is essential. Although medication for CTEPH is now available, PEA remains the preferred treatment option. BPA is another treatment option for patients with CTEPH.

• #2 New PAH Treatments Increase Patient Options – Pulmonary Hypertension Association

  https://phassociation.org/new-pah-treatments-increase-patient-options/

  Pulmonary hypertension treatment has come a long way since PHA’s founding in 1991. In the past week, the Food and Drug Administration approved the 15th and 16th treatments for pulmonary arterial hypertension. […] Last Friday, the FDA approved Johnson & Johnson’s Opsynvi, the first and only once-daily combination pill of macitentan and tadalafil. […] On Tuesday, the FDA approved Merck’s Winrevair (sotatercept-csrk), the first PAH drug that works on a new biological pathway different from those targeted by 14 existing FDA-approved treatments. […] Both treatments represent breakthroughs for the PH community. A once-daily pill offers increased convenience that can improve quality of life. And medication that works on a new pathway offers hope that PH can be reversed. […] Opsynvi can be taken by people who currently take 10 mg a day of macitentan and 40 mg of tadalafil in separate tablets.

• #2 Mechanisms and treatment of pulmonary arterial hypertension | Nature Reviews Cardiology

  https://www.nature.com/articles/s41569-024-01064-4

  Established therapies for pulmonary arterial hypertension (PAH), which has a complex vascular pathobiology characterized by cell proliferation, extracellular matrix deposition and inflammation, have predominantly vasodilatory effects. The tyrosine kinase inhibitors imatinib and seralutinib have predominantly anti-proliferative properties and have been reported to be efficacious in the treatment of PAH in clinical trials; administration by inhalation might address the safety concerns associated with orally administered imatinib. […] Therapy with the activin receptor type IIA ligand trap sotatercept was effective in patients with PAH in clinical trials; an ongoing extension study might address questions regarding long-term cardiac and systemic vascular safety. […] Individual responses to different PAH treatments might vary; deep phenotyping might help to identify biomarkers associated with drug-specific responses and support the development of a personalized medicine approach.

• #2 Managing Pulmonary Arterial Hypertension: Diagnosis, Classification, and Treatment Strategies

  https://www.pharmacytimes.com/view/managing-pulmonary-arterial-hypertension-diagnosis-classification-and-treatment-strategies

  For patients who meet the necessary criteria, Smith explained that vasoreactivity testing is performed. For this testing, 1 of 3 drugs is administered during right heart catheterization and the mPAP is watched to see if it drops in pressure. […] According to Smith, patients who are lower or intermediate risk will be started on oral combination therapies, such as macitentan and tadalafil (Opsynvi; Johnson Johnson), which is an EDN receptor agonist and PDE5 inhibitor that was approved in March 2024. For patients who are categorized as high risk, they would be started on the oral combination therapy and a PCN therapy. Once the regimen is initiated, the patient would then be reassessed in 3 to 6 months. […] The goal of pharmacotherapy is to get all patients to low risk, so if you’re reassessing a patient and they’re not low risk, you’re either going to be changing a drug, increasing the dose, or adding an additional agent, Smith said. If [the patient is] intermediate high or high risk, you would add a therapy or refer the patient to lung transplant, which would be the curative procedure for this disorder.

• #2 Natural Ways to Reduce Pulmonary Hypertension: Tips and Strategies

  https://www.healthline.com/health/how-to-reverse-pulmonary-hypertension-naturally

  Adopting healthy lifestyle behaviors may help lower blood pressure in your lungs and ease your symptoms. For example, you can try adjusting your diet, exercising more, and avoiding stimulants. […] While there isn’t a cure for the condition, medications, treatments, and lifestyle changes can help. […] Regular aerobic exercise can help you keep your heart healthy. This is especially important because keeping your heart and lungs functioning at their best can be difficult with pulmonary hypertension. […] A 2021 study suggests that a supervised exercise-based rehabilitation program is generally safe for most people with pulmonary hypertension who are otherwise medically stable. It found that the program could increase their capacity to do more exercise. […] By reducing the sodium in your diet, you can help prevent your pulmonary hypertension from getting worse.

• #2 Treating and Managing Pulmonary Arterial Hypertension | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/treating-and-managing

  It is also important to stay up to date on all recommended vaccinations. […] Quitting smoking and avoiding secondhand smoke is one of the most important decisions you can make. […] Though PAH may make you feel fatigued, it is important to stay active and exercise as much as possible. […] Eating healthy will be an important part of managing your disease. […] Pregnancy can put strain on your body and for a patient with PAH be possibly life-threatening, so this is a subject you should discuss with your healthcare provider prior to becoming pregnant. […] If Left Untreated, PAH Can Result in the Following: Right heart failure can occur due to increased stress on your heart. […] The most common cause of death in PAH is right heart ventricular failure. […] The outcome for untreated PAH is poor.

• #2 Natural Ways to Reduce Pulmonary Hypertension: Tips and Strategies

  https://www.healthline.com/health/how-to-reverse-pulmonary-hypertension-naturally

  A 2018 study suggests that managing fluid retention is a key part of keeping pulmonary hypertension under control. If your fluid levels are too high, your doctor might recommend medications such as diuretics. […] In addition to limiting your sodium intake, you should also make some careful dietary choices. […] Generally, a heart-healthy eating plan such as the Mediterranean diet or the Dietary Approaches to Stop Hypertension (DASH) diet will provide you with a range of healthy vitamins and minerals. […] If you have pulmonary hypertension, you might be taking medications that take extra stress off of your heart and lungs. However, it’s important to be aware that not all over-the-counter medications are safe for you to take. […] Smoking is not only a major risk factor for developing pulmonary hypertension, but it’s also a behavior that can make existing symptoms even worse.

• #2 Idiopathic Pulmonary Arterial Hypertension Treatment & Management: Approach Considerations, Calcium Channel Blocker Therapy, PAH-Specific Therapy

  https://emedicine.medscape.com/article/301450-treatment

  Currently, no precise dosage adjustment algorithm is available for patients with IPAH who are on PAH-specific therapy. […] To decrease the risk of developing pneumonia (which has been found to be the cause of death in 7% of patients with pulmonary arterial hypertension [PAH]), patients should receive vaccinations against influenza, Streptococcus pneumoniae, and SARS-CoV-2.

• #2 5 Pulmonary Hypertension Medications and Treatment Options | myPHteam

  https://www.myphteam.com/resources/treatments-for-pulmonary-hypertension

  When PH is caused by cardiovascular disease or lung disease, surgery may help in treating the underlying problem. […] A lung transplant may be an option for some people with PH whose condition is progressing and for whom medical therapy is no longer effective. […] Lifestyle changes can be an important part of managing PH symptoms. […] Making healthy nutrition choices can be an important way to improve PH symptoms. […] More recently, most PH specialists have come to believe that regular sessions of gentle exercise are safe and likely beneficial for those with PH. […] If you smoke, its suggested to quit. […] Pregnancy can be life-threatening for people with PH. […] Getting regular vaccinations for flu and pneumonia can help prevent dangerous infections in those with PH. […] Avoid situations and activities that can worsen PH symptoms.

• #2 Pulmonary Arterial Hypertension Treatment & Management: Approach Considerations, Oxygen Supplementation, Pharmacologic Therapy

  https://emedicine.medscape.com/article/303098-treatment

  Although lung transplantation is reserved for patients with severe pulmonary arterial hypertension (PAH), a number of patients have undergone successful transplantation at several centers. […] The majority of cases of pulmonary arterial hypertension (PAH) are not preventable. […] Once a diagnosis of pulmonary arterial hypertension (PAH) has been made, patients should be evaluated at regular intervals by a PAH specialist.

• #2 Pulmonary Hypertension: Diagnosis and Treatment | AAFP

  https://www.aafp.org/pubs/afp/issues/2016/0915/p463.html

  Pulmonary hypertension is a common, complex group of disorders that result from different pathophysiologic mechanisms but are all defined by a mean pulmonary arterial pressure of 25 mm Hg or greater. […] For certain categories of pulmonary hypertension, particularly pulmonary arterial hypertension, treatment options are rapidly evolving, and early diagnosis and prompt referral to an expert center are critical to ensure the best prognosis. […] There are no directed therapies for many other categories of pulmonary hypertension; therefore, family physicians have a central role in managing contributing comorbidities. […] Results from invasive hemodynamic testing with right heart catheterization, preferably at an expert center, should be obtained before initiating treatment with vasodilator therapy in patients with pulmonary arterial hypertension.

• #3 Pulmonary Hypertension: Symptoms, Treatment

  https://my.clevelandclinic.org/health/diseases/6530-pulmonary-hypertension-ph

  Pulmonary hypertension treatment depends on the type of PH you have and your other medical conditions. Your healthcare team will tailor treatment to your individual needs. […] Right now, only two types of PH can be treated directly: Pulmonary artery hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH). […] Treatment for pulmonary arterial hypertension (PAH) includes: Calcium channel blockers. These medications can help lower the blood pressure in your pulmonary arteries and throughout your body. Diuretics. These water pills help your body clear out extra fluid. Oxygen therapy. You may need this treatment if you don’t have enough oxygen in your blood. Pulmonary vasodilators. These medications help your pulmonary arteries relax and open up better. This improves blood flow and lowers the strain on your heart.

• #3 Pulmonary Hypertension | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/pulmonary-hypertension

  If you have secondary pulmonary hypertension, treatment will generally focus on addressing the underlying cause. For instance, if a blood clot led to your hypertension, treatment may be to surgically remove the clot. […] A number of treatments are used to manage primary pulmonary hypertension, though they won’t cure the condition. These include: […] Calcium channel blockers. These drugs help the heart pump better by relaxing muscles in the walls of blood vessels. […] Endothelin receptor antagonists (ERAs). These drugs reverse the effects of endothelin, a substance produced in blood vessels that makes them constrict. […] Epoprostenol. This medication dilates and reverses thickening of the lungs’ blood vessels and helps prevent platelets (cell fragments in blood that stop bleeding) from clotting the blood. It’s infused intravenously (into a vein) using a portable pump.

• #3 Pulmonary Hypertension: Diagnosis and Treatment | AAFP

  https://www.aafp.org/pubs/afp/issues/2016/0915/p463.html/1000

  Patients with a mean pulmonary arterial pressure decrease of more than 10 mm Hg to less than 40 mm Hg and with an unchanged or increased cardiac output when challenged are considered vasoreactive. […] Other treatments may include an endothelin receptor antagonist (bosentan [Tracleer]), a phosphodiesterase type 5 inhibitor (sildenafil [Revatio]), or a soluble guanylate cyclase stimulator (riociguat [Adempas]). […] A pulmonary endarterectomy performed at a center of excellence can be curative and is first-line therapy in patients with chronic thromboembolic pulmonary hypertension who are surgical candidates. […] The focus for these patients is optimizing the underlying heart disease and controlling comorbidities. […] The treatment of pulmonary hypertension due to lung disease should focus on managing the underlying lung disease and optimizing treatment of other comorbidities. […] Patients with chronic lung disease and severe pulmonary hypertension should consult with a subspecialist. […] There are limited data on the treatment of pulmonary hypertension for most of the etiologies in this group.

• #3 Pulmonary Hypertension: Symptoms, Treatment

  https://my.clevelandclinic.org/health/diseases/6530-pulmonary-hypertension-ph

  Treatment for CTEPH includes: Anticoagulants. These medicines help prevent blood clots. Balloon atrial septostomy (BAS). This procedure is typically used for babies with critical heart defects. However, it’s also used for adults with pulmonary hypertension. It’s a bridge that helps keep you stable as you wait for a lung transplant. Balloon pulmonary angioplasty (BPA). This catheter-based procedure uses a balloon to widen your pulmonary artery. It’s usually done if you can’t have open surgery. Medication. A soluble guanylate cyclase stimulator (SGCS) may help slow down the disease progression. Pulmonary endarterectomy (PEA). This surgery removes blood clots from your lungs. It’s currently the only possible cure for pulmonary hypertension, and it’s only for people with CTEPH. […] Treatment for PH caused by heart or lung problems focuses on managing the underlying conditions. Because so many different heart and lung conditions cause PH, treatment plans can be vastly different from person to person.

• #3 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  Veletri is a new formulation of Epoprostenol approved by the FDA in 2010 for the treatment of PAH, as well as pulmonary hypertension related to scleroderma, lupus, congenital heart disease, diet-pill associated and stimulant associated PH. It is for patient with severe disease that have not responded to conventional therapy. Substantial commitment is required from the patient in order to use this medication as it is a continuous infusion via an intravenous catheter via an ambulatory infusion pump. Different to Flolan, Veletri requires less frequent mixing and does not have to be continuously refrigerated. The side effects are the same as with Flolan and again meticulous attention must be paid to catheter care to prevent serious infections. […] This medication is structurally related to epoprostenol (Flolan). It is approved for the treatment of PAH, and pulmonary hypertension due to connective tissue disease. There is also experience with this drug in congenital heart disease. Studies have shown that Remodulin increases exercise tolerance and decreases pulmonary artery pressure. The drug is delivered by a continuous infusion either intravenous or subcutaneous. If indicated, the subcutaneous formulation is infused underneath the skin in the abdomen via a very small plastic catheter. Side effects are similar to Flolan. Although the delivery system is complex, it is somewhat less so than Flolan. Remodulin does not need to be mixed or refrigerated. Infusion site pain for the subcutaneous formulation remains a significant problem with this medication for many patients. Periodic monitoring of blood counts is required.

• #3 Treatments for Pulmonary Arterial Hypertension: Pills, Inhaled Drugs, Oxygen

  https://www.webmd.com/lung/pah-treatment-options

  Warfarin (Coumadin) thins your blood to keep clots from building up, which can make PAH worse. […] Medicines that keep excess fluid out of the body, called diuretics, can make the heart and lungs work better and ease the symptoms of PAH. […] Other PAH pills lower the blood pressure in the pulmonary arteries by keeping blood vessels open or preventing them from narrowing. […] Drugs called vasodilators open up blood vessels, but some have an effect on the body for only a few minutes. […] Some people with PAH need oxygen therapy to get enough oxygen in their blood. […] If you have severe PAH or medications dont help your symptoms, your doctor may recommend one of two types of operations: […] Atrial septostomy: A surgeon makes an opening between the upper chambers of the left and right sides of your heart to lower the pressure on one side. […] Lung and heart transplants: Doctors recommend them for people who have tried drugs to treat their disease without success and whose condition is getting worse. […] A transplant can improve your life, but its serious surgery.

• #3 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  Warfarin (Coumadin) is prescribed for most patients with pulmonary arterial hypertension. There is some data from research studies that this medication may improve survival as patients with PAH are at increased risk to develop blood clots. It requires monitoring to adjust the dose. There are many medications and foods that interact with warfarin. In general, patients on Warfarin should avoid aspirin containing products. […] Most if not all patients with pulmonary hypertension will require a diuretic to prevent retention of salt and water. Commonly prescribed agents include furosemide (Lasix), bumetinide (Bumex), and spironolactone (Aldactone). These medications are usually prescribed once daily initially, but in patients with more advanced disease, escalated dosing and combinations are often required. Patients must pay close attention to their diets and avoid high salt foods and limit their intake of liquids. Periodic monitoring of blood chemistries is required, and many patients require supplemental potassium.

• #3 Pulmonary Hypertension | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/pulmonary-hypertension

  Anticoagulants. Often called blood thinners, these drugs keep blood from clotting, allowing circulating blood to flow more easily. […] Diuretics. These medications minimize water retention which can make the heart work harder by making the kidneys produce more urine. […] Digoxin. This drug can help the right side of the heart pump better, but patients receiving it need to be closely monitored. […] Supplemental oxygen. For patients with low blood oxygen levels, concentrated oxygen may be delivered using in-home machines and portable devices. […] When all other options have failed, patients with severe pulmonary hypertension and poor quality of life may be candidates for lung transplantation or heart-lung transplantation. […] Adequate rest, a healthy diet, exercise and stress reduction can help control pulmonary hypertension. People with the disease should avoid smoking, becoming pregnant, using birth control pills and being at high altitudes. […] Pulmonary hypertension treatment is often highly complex and patients require intensive ongoing follow-up. This comprehensive care is available from the specialists of the UCSF Pulmonary Hypertension Program.

• #3 Treating and Managing Pulmonary Arterial Hypertension | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/treating-and-managing

  Treatment aims to restore balance among one or more of three substances that are produced by your lungs: nitric oxide, endothelin, and prostacyclin. […] Your healthcare provider may recommend supportive treatment to manage your PAH. […] One or more of the following medications may be recommended: Blood thinners to prevent blood clots, Digoxin to help your heart beat regularly, Water pills, also called diuretics, to remove extra fluid from your body, Oxygen therapy to make sure you are getting enough oxygen. […] Surgery may be recommended in some situations. […] Atrial septostomy is a procedure that creates an opening between the upper left and right chambers of the heart. The opening reduces the pressure on the right side of the heart. […] Many pulmonary hypertension care centers require visits every few months and regular testing such as echocardiograms and 6-minute walk testing.

• #3 Pulmonary Hypertension: Diagnosis, Management, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6433622/

  Exercise should be limited to a symptom-free level for maintaining adequate skeletal muscle conditioning. […] Patients who have been newly diagnosed with idiopathic, heritable, or drug-related PH that are identified as responders by vasoreactivity testing should be treated with a calcium antagonist. For non-responders, PAH-specific drugs should be considered. PAH-specific drugs target the endothelin, nitric oxide, or prostacyclin pathways. […] When the treatment response is inadequate despite maximal medical therapy, referral for lung transplant evaluation should be considered. […] All patients should be treated using life-long anticoagulant therapy, i.e. vitamin K antagonists, with a target international normalized ratio of 1.52.5. […] Pulmonary endarterectomy (PEA) is the standard of care for patients with operable CTEPH.

• #3 New Treatment Options for Pulmonary Hypertension Patients | NYU Langone News

  https://nyulangone.org/news/new-treatment-options-pulmonary-hypertension-patients

  Zachary N. Kon, MD, surgical director of the lung transplantation program and assistant professor in the Department of Cardiothoracic Surgery, leads a program to treat chronic thromboembolic pulmonary hypertension (CTEPH). […] Dr. Kon is one of a small number of surgeons trained to perform this delicate surgery, which is the definitive treatment for CTEPH. […] Dr. Kon has begun performing the procedure using a less invasive incision that avoids a full median sternotomy. It translates into faster recovery time, less postoperative pain, and improved cosmetic resultswithout sacrificing outcome, says Dr. Kon. […] Next, NYU Langone is gearing up to provide a new cutting-edge treatment option that could benefit additional CTEPH patients: balloon pulmonary angioplasty.

• #3 Pulmonary Hypertension: Symptoms, Treatment

  https://my.clevelandclinic.org/health/diseases/6530-pulmonary-hypertension-ph

  A last resort option for some people with severe pulmonary hypertension is a lung transplant. […] Pulmonary vasodilators are medications that treat PAH and CTEPH. They can’t be used for other types of PH, including those caused by underlying heart or lung issues. […] People with PH may take a variety of other medications based on their underlying conditions.

• #3 New PAH Treatments Increase Patient Options – Pulmonary Hypertension Association

  https://phassociation.org/new-pah-treatments-increase-patient-options/

  Pulmonary hypertension treatment has come a long way since PHA’s founding in 1991. In the past week, the Food and Drug Administration approved the 15th and 16th treatments for pulmonary arterial hypertension. […] Last Friday, the FDA approved Johnson & Johnson’s Opsynvi, the first and only once-daily combination pill of macitentan and tadalafil. […] On Tuesday, the FDA approved Merck’s Winrevair (sotatercept-csrk), the first PAH drug that works on a new biological pathway different from those targeted by 14 existing FDA-approved treatments. […] Both treatments represent breakthroughs for the PH community. A once-daily pill offers increased convenience that can improve quality of life. And medication that works on a new pathway offers hope that PH can be reversed. […] Opsynvi can be taken by people who currently take 10 mg a day of macitentan and 40 mg of tadalafil in separate tablets.

• #3 New PAH Treatments Increase Patient Options – Pulmonary Hypertension Association

  https://phassociation.org/new-pah-treatments-increase-patient-options/

  Winrevair is a subcutaneous injection given every three weeks. The injection is taken in combination with other PAH treatments. People who took Winrevair in clinical trials showed significantly improved exercise capacity and slower disease progression. […] Winrevair targets an imbalance in activin-growth differentiation factor and BMP pathways signaling. […] Winrevair works to reduce and possibly reverse proliferation of cells in the vascular wall. […] Fortunately, several other new treatments are under development, including seralutinib, by Gossamer Bio and imatinib by Aerovate. […] We welcome the development of new therapies for those with PAH. […] Despite the availability of 16 PAH treatments in the US, we know PH research has a long way to go. We still need medications for other forms of PH, and we need better accessibility to treatment in other parts of the world.

• #3 Pulmonary Hypertension – Treatment | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/pulmonary-hypertension/treatment

  If you are diagnosed with pulmonary hypertension, your doctor will determine your treatment plan based on the cause of disease, if it is known. There is usually no cure for pulmonary hypertension, but there are ways to keep your symptoms from getting worse. Your doctor will recommend the best management plan for you. […] Medicines to treat pulmonary hypertension may include: […] Your doctor may recommend a procedure, surgery, or therapy to treat pulmonary hypertension. […] Your doctor may recommend medicines or procedures to treat the condition that is causing your pulmonary hypertension.

• #4 Pulmonary Arterial Hypertension (PAH): Symptoms and Treatment

  https://my.clevelandclinic.org/health/diseases/23913-pulmonary-arterial-hypertension

  Calcium channel blockers. These medications help lower the blood pressure in your pulmonary arteries and throughout your body. […] Diuretics. These water pills get rid of extra fluid in your body and reduce swelling. […] Oxygen therapy. You may need this treatment if you dont have enough oxygen in your blood. Supplemental oxygen can help people during rest, sleep or exercise. […] Pulmonary vasodilators. These medications help your pulmonary arteries relax and open up better. This relieves the strain on your heart and helps ease your symptoms. […] A last resort option for some people with severe PAH is a lung transplant. This surgery may give you one or two new lungs. A heart-lung transplant gives you a new heart as well. […] Medications that treat PAH come in several different forms: Oral. To help the blood vessels in your lungs relax, and to prevent them from becoming narrow. These medications may help you be more physically active.

• #4 Pulmonary Hypertension: Diagnosis and Treatment | AAFP

  https://www.aafp.org/pubs/afp/issues/2016/0915/p463.html

  Patients with a mean pulmonary arterial pressure decrease of more than 10 mm Hg to less than 40 mm Hg and with an unchanged or increased cardiac output when challenged are considered vasoreactive. […] Other treatments may include an endothelin receptor antagonist (bosentan [Tracleer]), a phosphodiesterase type 5 inhibitor (sildenafil [Revatio]), or a soluble guanylate cyclase stimulator (riociguat [Adempas]). […] A pulmonary endarterectomy performed at a center of excellence can be curative and is first-line therapy in patients with chronic thromboembolic pulmonary hypertension who are surgical candidates. […] Patients who are not surgical candidates can be considered for targeted medical therapies also used to treat pulmonary arterial hypertension. […] The use of therapies targeted at pulmonary arterial hypertension is strongly discouraged.

• #4 FDA-approved Treatments for Pulmonary Hypertension | Vera Moulton Wall Center for Pulmonary Vascular Disease | Stanford Medicine

  https://med.stanford.edu/wallcenter/patient-resources/fda.html

  As a result of small but favorable studies, sildenafil was tested and found useful in trials for patients with New York Heart Association (NYHA) Class II-IV pulmonary arterial hypertension. Sildenafil is an active vasodilator and allows for improved pulmonary blood flow. Sildenafil is currently approved for patient with PAH in the formulation of Revatio. The usual dose of 20 mg three times daily is the current recommendation by the FDA. However, patients with severe PAH may often require higher, and more frequent, dosing. Although used for erectile dysfunction in men, sildenafil has not been shown to affect sexual desire in men, nor does it have any effect in women. Side effects of sildenafil include headache, back pain, and flushing. The use of sildenafil is contraindicated in patients using nitrate containing medications such as isordil or sub-lingual nitroglycerin. Other drug interactions include alpha-blockers (such as Doxazosin), certain antibiotics, and verapamil (which may increase sildenafil serum concentration). Bosentan and sildenafil, when taken together, co-interact and result in elevated bosentan and decreased sildenafil levels. Patients with coronary artery disease need to notify their physician before using sildenafil.

• #4 Pulmonary Hypertension: Diagnosis and Treatment | AAFP

  https://www.aafp.org/pubs/afp/issues/2016/0915/p463.html/1000

  Patients with a mean pulmonary arterial pressure decrease of more than 10 mm Hg to less than 40 mm Hg and with an unchanged or increased cardiac output when challenged are considered vasoreactive. […] Other treatments may include an endothelin receptor antagonist (bosentan [Tracleer]), a phosphodiesterase type 5 inhibitor (sildenafil [Revatio]), or a soluble guanylate cyclase stimulator (riociguat [Adempas]). […] A pulmonary endarterectomy performed at a center of excellence can be curative and is first-line therapy in patients with chronic thromboembolic pulmonary hypertension who are surgical candidates. […] The focus for these patients is optimizing the underlying heart disease and controlling comorbidities. […] The treatment of pulmonary hypertension due to lung disease should focus on managing the underlying lung disease and optimizing treatment of other comorbidities. […] Patients with chronic lung disease and severe pulmonary hypertension should consult with a subspecialist. […] There are limited data on the treatment of pulmonary hypertension for most of the etiologies in this group.

• #4 New PAH Treatments Increase Patient Options – Pulmonary Hypertension Association

  https://phassociation.org/new-pah-treatments-increase-patient-options/

  Winrevair is a subcutaneous injection given every three weeks. The injection is taken in combination with other PAH treatments. People who took Winrevair in clinical trials showed significantly improved exercise capacity and slower disease progression. […] Winrevair targets an imbalance in activin-growth differentiation factor and BMP pathways signaling. […] Winrevair works to reduce and possibly reverse proliferation of cells in the vascular wall. […] Fortunately, several other new treatments are under development, including seralutinib, by Gossamer Bio and imatinib by Aerovate. […] We welcome the development of new therapies for those with PAH. […] Despite the availability of 16 PAH treatments in the US, we know PH research has a long way to go. We still need medications for other forms of PH, and we need better accessibility to treatment in other parts of the world.

• #4 Study finds new treatment for pulmonary hypertension holds promise

  https://health.ucdavis.edu/news/headlines/study-finds-new-treatment-for-pulmonary-hypertension-holds-promise/2023/08

  A study led by The Goncharova lab at UC Davis Health has validated a potential therapy to treat pulmonary arterial hypertension. […] According to the study published in Science Signaling, restoring the functional growth suppressor tuberous sclerosis complex 2 (TSC2) may help to reverse existing pulmonary vascular remodeling and pulmonary arterial hypertension. […] The team discovered the growth suppressor TSC2 is virtually absent in vascular smooth muscle cells in small pulmonary arteries. Additionally, they found that TSC2 controls cell growth caused by mechanical biological cues meaning if it is present, it can block the stiffening and remodeling of pulmonary arteries. […] Next, the team began to evaluate potential medication strategies to restore functional TSC2 in pulmonary arterial vascular smooth muscle cells.

Zobacz więcej